Summary
Peadiatric inflammatory multisystem syndrome associated with COVID-19 is a new term that describes the COVID-19-associated multi-system inflammatory syndrome in children, which appeared in medical terminology with the spread of the SARS-CoV-2 pandemic. The connection with a past SARS-CoV-2 infection can usually be demonstrated by means of laboratory and molecular tests. The course of the disease is associated with dysfunction of the immune system, hence the clinical picture may be very similar to Kawasaki disease (initially this syndrome was called 'Kawasaki disease-like'). Cardiac complications, including heart failure, were also observed in PIMS. Therefore, cardiological diagnostics is necessary in every child diagnosed with PIMS.
Moreover, it should be noted that a patient diagnosed with PIMS should be under the supervision of a multidisciplinary team of doctors. Both the treatment od PIMS and the clinical picture are similar to the treatment of Kawasaki disease. It is mainly based on the use of intravenous immunoglobulin, anticoagulants, and sometimes also glucocorticosteroids. After treatment, cardiological control is necessary due to possible complications in the cardiovascular system.